BioNexus Gene Lab (BGLC) Receivables - Net (2020 - 2026)

BioNexus Gene Lab (BGLC) has 7 years of Receivables - Net data on file, last reported at $958763.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 33.52% year-over-year to $958763.0; the trailing twelve-month figure through Mar 2026 stood at $958763.0 (down 33.52% YoY), and the FY2025 full-year result was $1.2 million, down 36.14% from the prior year.
• Receivables - Net rose to $958763.0 in Q1 2026, from $505885.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $3.0 million in Q1 2022 to a low of $505885.0 in Q4 2025.
• A 5-year average of $1.7 million and a median of $1.5 million in 2025 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net soared 136.9% in 2024 and sank 73.3% in 2025, its largest moves.
• Tracing BGLC's Receivables - Net over 5 years: stood at $2.9 million in 2022, then sank by 72.12% to $799674.0 in 2023, then surged by 136.9% to $1.9 million in 2024, then slumped by 73.3% to $505885.0 in 2025, then soared by 89.52% to $958763.0 in 2026.
• Business Quant data shows BGLC's Receivables - Net at $958763.0 in Q1 2026, $505885.0 in Q4 2025, and $1.5 million in Q3 2025.